News coverage about Cutera (NASDAQ:CUTR) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cutera earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 45.1681575975249 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Cutera (CUTR) traded down 1.37% on Friday, reaching $43.35. 81,727 shares of the company’s stock traded hands. Cutera has a 52 week low of $12.45 and a 52 week high of $44.40. The firm has a market capitalization of $607.12 million, a price-to-earnings ratio of 93.23 and a beta of 0.53. The company has a 50 day moving average price of $38.60 and a 200 day moving average price of $27.34.

Cutera (NASDAQ:CUTR) last released its quarterly earnings results on Monday, August 7th. The medical device company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.10. Cutera had a net margin of 5.07% and a return on equity of 11.64%. The company had revenue of $36.40 million for the quarter, compared to the consensus estimate of $32.08 million. During the same period in the previous year, the firm earned $0.07 EPS. Cutera’s revenue was up 32.4% on a year-over-year basis. On average, equities research analysts predict that Cutera will post $0.52 earnings per share for the current fiscal year.

Cutera announced that its board has approved a share repurchase program on Monday, August 7th that authorizes the company to buyback $25.00 million in outstanding shares. This buyback authorization authorizes the medical device company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its shares are undervalued.

A number of brokerages have recently issued reports on CUTR. Roth Capital boosted their price target on shares of Cutera from $41.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, September 12th. Maxim Group lowered shares of Cutera from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. BidaskClub upgraded shares of Cutera from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. TheStreet upgraded shares of Cutera from a “c” rating to a “b” rating in a research note on Friday, August 18th. Finally, Gabelli reiterated a “buy” rating on shares of Cutera in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Cutera currently has an average rating of “Buy” and an average price target of $37.33.

ILLEGAL ACTIVITY WARNING: “Cutera (CUTR) Getting Somewhat Positive Press Coverage, Study Finds” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at

In other news, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $38.45, for a total value of $38,450.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Ronald J. Santilli sold 28,519 shares of Cutera stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $34.01, for a total transaction of $969,931.19. Following the completion of the transaction, the executive vice president now directly owns 75,253 shares in the company, valued at approximately $2,559,354.53. The disclosure for this sale can be found here. Insiders have sold a total of 56,309 shares of company stock worth $1,965,520 over the last 90 days. 11.60% of the stock is owned by insiders.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Insider Buying and Selling by Quarter for Cutera (NASDAQ:CUTR)

Receive News & Stock Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related stocks with our FREE daily email newsletter.